ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1313 • 2014 ACR/ARHP Annual Meeting

    Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry

    Marc D. Natter1, Mei-Sing Ong2, Kenneth D. Mandl3, Laura Schanberg4, Yukiko Kimura5, Norman Ilowite6 and the CARRA Registry Investigators, 1Intelligent Health Labs, Children's Hospital Boston, Boston, MA, 2Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, 3Intelligent Health Lab, Children's Hospital Boston, Boston, MA, 4Duke University, Durham, NC, 5Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, 6Rheumatology, Children's Hospital Montefiore, Bronx, NY

    Background/Purpose: Knowledge of co-occurring disease processes (comorbidities) is important for understanding disease pathogenesis, refining disease classifications, developing appropriate screening and prevention strategies, and determining overall…
  • Abstract Number: 1312 • 2014 ACR/ARHP Annual Meeting

    Features, Treatment and Outcome of Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus

    Roberto Ezequiel Borgia1, Maya Gerstein1, Deborah M. Levy2, Earl D. Silverman1 and Linda T Hiraki3, 1Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening inflammatory complication of pediatric systemic lupus erythematosus (pSLE). There are few reports of the presentation, treatment and outcome of…
  • Abstract Number: 1311 • 2014 ACR/ARHP Annual Meeting

    Lupus Nephritis in Mexican Children

    María del Rocío Maldonado-Velázquez1, Enrique Faugier1, Fernando Garcia-Rodriguez2, Paola Lara1, Angel Flores1, Javier Tomala-Haz1 and Diego Salinas-Encinas1, 1Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, 2Rheumatology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico

    Background/PurposeIncidence and disease pattern of childhood-onset systemic lupus erythematosus (SLE) is reported to differ among ethnic groups. Lupus nephritis (LN) strongly affects the outcome in…
  • Abstract Number: 1310 • 2014 ACR/ARHP Annual Meeting

    Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis

    Maya Gerstein1, Roberto Ezequiel Borgia2, Brian Feldman1, Deborah M. Levy3, Sharon Sukhdeo4, Susanne M. Benseler5, Lawrence W.K. Ng1, Mohamed Abdelhaleem6, Earl D. Silverman2 and Linda T Hiraki7, 1Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 2Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 3Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 4Rheumatology, The Hospital For Sick Children, Toronto, ON, Canada, 5Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, 6Department of Paediatric Laboratory Medicine, Division of Haematopathology, The Hospital for Sick Children, Toronto, ON, Canada, 7The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose It can be difficult to differentiate macrophage activation syndrome (MAS) from active pediatric systemic lupus erythematosus (pSLE). However, this differentiation is in determining correct…
  • Abstract Number: 1309 • 2014 ACR/ARHP Annual Meeting

    Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood – Onset Systemic Lupus Erythematosus?

    Thaschawee Arkachaisri1, Joo Guan Yeo2, Justin Hung Tiong Tan3, Sook Fun Hoh4, Lena Das3 and Jing Yao Leong2, 1Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 2Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, 3Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 4Nursing, KK Women's and Children's Hospital, Singapore, Singapore

    Background/Purpose: Biomarkers proven to be effective in aSLE patients may not directly apply to cSLE unless validation is done. Existing evidences have shown immunopathogenic roles…
  • Abstract Number: 1308 • 2014 ACR/ARHP Annual Meeting

    Antinucleosome Antibodies As Potential Diagnostic and Prognostic Biomarkers in Childhood Onset Systemic Lupus Erythematosus

    Thaschawee Arkachaisri1, Joo Guan Yeo2, Justin Hung Tiong Tan3, Sook Fun Hoh4, Lena Das3 and Jing Yao Leong2, 1Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 2Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, 3Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, 4Nursing, KK Women's and Children's Hospital, Singapore, Singapore

    Background/Purpose: The role of antinucleosome antibodies (ANuA) in the immunopathogenesis of SLE is evident. ANuA was shown to be a good, if not better than…
  • Abstract Number: 1307 • 2014 ACR/ARHP Annual Meeting

    Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients

    Joyce S Hui-Yuen1, Kristi Truong2, Liza Mariel Bermudez-Santiago1, Amy J. Starr3, Andrew Eichenfield4, Lisa F. Imundo5 and Anca Askanase3, 1Morgan Stanley Children's Hospital of New York Presbyterian, Columbia University Medical Center, New York, NY, 2Doctor of Pharmacy degree program, St John's University, Queens, NY, 3Columbia University Medical Center, New York, NY, 4Div of Pediatric Rheumatology, Children's Hosp of New York, New York, NY, 5Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY

    Background/Purpose: Mycophenolate mofetil (MMF) is often used to treat lupus nephritis (LN) and extra-renal lupus in children with SLE. Plasma levels of mycophenolic acid (MPA)…
  • Abstract Number: 1306 • 2014 ACR/ARHP Annual Meeting

    Outcome of Lupus Nephritis in Children Less Than 12 Years Old from North-India

    Anju Gupta, Bonnie Abujam, Deepti Suri, Amit Rawat and Surjit Singh, Postgraduate Institute of Medical Education and Research, Chandigarh, India

    Background/Purpose  Studies on lupus nephritis in young children below 12 years of age from developing countries are limited. This study looks at long-term outcome in…
  • Abstract Number: 1305 • 2014 ACR/ARHP Annual Meeting

    Adiposity and Adipokines Are Associated with Insulin Resistance in Pediatric Systemic Lupus Erythematosus

    Leandra Uribe Woolnough1,2, Tracey Wright2,3 and Gloria Vega4, 1Pediatrics, UT Southwestern Medical Center, Dallas, TX, 2Children's Medical Center, Dallas, TX, 3Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, 4Center for Human Nutrition, UTSouthwestern Medical Center, Dallas, TX

    Background/Purpose: Traditional risk factors for cardiovascular disease do not fully account for the increase in atherosclerosis in SLE.  Insulin resistance (IR) and other metabolic derangements…
  • Abstract Number: 1304 • 2014 ACR/ARHP Annual Meeting

    Development of an Index to Non-Invasively Quantify Lupus Nephritis Chronicity in Children

    Khalid Abulaban1, Michael Bennett2, Marisa Klein-Gitelman3, Stacy P. Ardoin4, Kelly A. Rouster-Stevens5, Lori B. Tucker6, Kasha Wiley7, Shannen Nelson8, Karen Onel9, Nora G. Singer10, Kathleen M. O'Neil11, B Anne Eberhard12, Lawrence K. Jung13, Lisa F. Imundo14, Tracey Wright15, David Witte16, Jun Ying17, Prasad Devarajan2 and Hermine I. Brunner18, 1Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, 4Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 5Pediatrics, Emory University School of Medicine, Atlanta, GA, 6Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 7Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 10Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 11Division of Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, 12Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, 13Pediatric Rheumatology, Children's National Medical Center, Washington, DC, 14Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, 15Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, 16Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, 17University of Cincinnati, Cincinnati, OH, 18Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: The current gold standard for assessing chronic changes in Lupus Nephritis (LN) is a kidney biopsy interpreted using the International Societies for Nephrology &…
  • Abstract Number: 1303 • 2014 ACR/ARHP Annual Meeting

    Accuracy of Laboratory Measures and Clinical Renal Activity Indices for Reflecting Biopsy-Proven Lupus Nephritis (LN) Activity

    Khalid Abulaban1, Stacy P. Ardoin2, Marisa Klein-Gitelman3, Kelly A. Rouster-Stevens4, Michael Bennett5, Lori B. Tucker6, Kasha Wiley7, Shannen Nelson8, Karen Onel9, Nora G. Singer10, B Anne Eberhard11, Kathleen M. O'Neil12, Elizabeth B. Brooks13, Lawrence K. Jung14, Lisa F. Imundo15, Tracey Wright16, David Witte17, Jun Ying18, Prasad Devarajan5 and Hermine I. Brunner19, 1Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 3Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, 4Pediatrics, Emory University School of Medicine, Atlanta, GA, 5Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 6Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 7Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 10Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 11Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, 12Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, 13Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Case Medical Center, Cleveland, OH, 14Pediatric Rheumatology, Children's National Medical Center, Washington, DC, 15Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, 16Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, 17Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, 18University of Cincinnati, Cincinnati, OH, 19Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose :  LN is common in childhood-onset Systemic Lupus Erythematosus (cSLE). Kidney biopsies are impractical to assess the course of LN given their invasiveness and…
  • Abstract Number: 1321 • 2014 ACR/ARHP Annual Meeting

    A Pilot Study to Evaluate the Feasibility of Conducting Juvenile Localized Scleroderma Comparative Effectiveness Treatment Studies

    Suzanne C. Li1, Kathryn S. Torok2, Mara L Becker3,4, Fatma Dedeoglu5, Polly J. Ferguson6, Robert C. Fuhlbrigge7,8, Gloria C. Higgins9, Sandy D. Hong10, Maria F. Ibarra11, Ronald Laxer12, Thomas G. Mason II13, Elena Pope14, Marilynn G. Punaro15, C. Egla Rabinovich16, Katie G. Stewart15 and Brian Feldman17, 1Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 2Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 3Rheumatology, Children's Mercy Hospital, Kansas City, MO, 4Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, 5Rheumatology, Boston Children's Hospital, Boston, MA, 6Dept of Pediatrics--Rheum, University of Iowa Carver College of Medicine, Iowa City, IA, 7Department of Dermatology, Brigham and Women's Hospital, Boston, MA, 8Division of Immunology, Boston Children's Hospital, Boston, MA, 9Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, 10Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, 11Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, 12Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 13Rheumatology, Mayo Clinic Rochester, Rochester, MN, 14Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, 15Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, 16Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, 17Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose   Juvenile localized scleroderma (jLS) often causes severe morbidity in the developing child, including growth defects and disfigurement. Optimal therapy is not known.  The…
  • Abstract Number: 1320 • 2014 ACR/ARHP Annual Meeting

    Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus

    Kyla D. Driest1, Mollie S. Sturm2, Sarah H. O'Brien3, Charles H. Spencer4 and Stacy P. Ardoin5, 1Rheumatology, OSU Pediatrics, Nationwide Children's Hospital, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Hematology, Nationwide Children's Hospital, Columbus, OH, 4Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 5Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher thrombotic risk compared to the general population, and arterial and venous thromboses impart substantial morbidity…
  • Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting

    Safety of Rituximab in Treating Pediatric Rheumatologic Disease

    Arunima Agarwal1, Anusha Ramanathan2 and Rhina Castillo3, 1Pediatric Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, 2Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, 3Pediatric Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA

    Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…
  • Abstract Number: 1318 • 2014 ACR/ARHP Annual Meeting

    Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups

    Gulnara Mamyrova1, Lan Wu2, Adam Huber3, Ira N. Targoff4, Frederick W. Miller2 and Lisa G. Rider2, 1Rheumatology, George Washington University, Washington, DC, 2Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 3IWK Health Centre, Halifax, NS, Canada, 4Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: To evaluate features of JIIM clinical and Ab subgroups at illness onset.  Methods: Physician-completed questionnaires illness onset features were reviewed in 465 JIIM pts…
  • « Previous Page
  • 1
  • …
  • 1962
  • 1963
  • 1964
  • 1965
  • 1966
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology